Literature DB >> 21243931

Leukocyte phenotype changes induced by specific immunotherapy in patients with birch allergy.

A Månsson1, O Bachar, M Adner, S Björnsson, L O Cardell.   

Abstract

BACKGROUND: The underlying mechanisms of allergen-specific immunotherapy (SIT) are not fully understood.
OBJECTIVES: The present study aimed to investigate how leukocyte phenotypes are affected by SIT.
METHODS: Blood samples were taken from 10 patients with birch pollen--induced allergic rhinitis before, during, and immediately after SIT. Further samples were obtained after 1 year and 3 years. All samples were analyzed by flow cytometry and leukocyte differentiation.
RESULTS: SIT caused a decrease in cell-bound immunoglobulin (Ig) E on granulocytes, along with a corresponding increase in the high-affinity IgG receptor. Accordingly, a lower level of allergen-specific IgE was found after 3 years. The treatment induced a decrease in neutrophil CD1 1b levels, a shift in monocyte subsets, and an increase in the number of activated T lymphocytes, manifested as an upregulation of CD69 and CD98, and an expansion of the CD4+CD25+ T-cell pool.
CONCLUSION: The present study shows that the clinical effects of SIT are mirrored by systemic changes in cellular events and in antibodies, and offers new targets for immunomodulation.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21243931

Source DB:  PubMed          Journal:  J Investig Allergol Clin Immunol        ISSN: 1018-9068            Impact factor:   4.333


  2 in total

1.  FoxP3 Tregs Response to Sublingual Allergen Specific Immunotherapy in Children Depends on the Manifestation of Allergy.

Authors:  Anna Stelmaszczyk-Emmel; Anna Zawadzka-Krajewska; Eliza Głodkowska-Mrówka; Urszula Demkow
Journal:  J Immunol Res       Date:  2015-09-20       Impact factor: 4.818

2.  Immunotherapy reduces allergen-mediated CD66b expression and myeloperoxidase levels on human neutrophils from allergic patients.

Authors:  Rocio Aroca; Cristina Chamorro; Antonio Vega; Inmaculada Ventura; Elisa Gómez; Ramón Pérez-Cano; Miguel Blanca; Javier Monteseirín
Journal:  PLoS One       Date:  2014-04-16       Impact factor: 3.240

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.